In 2012, the shares of Novo Nordisk were priced at around $14 and its market cap was $90 billion. In July 2021, following the approval for the weight loss drug, its market cap hovered at $190 billion. The race includes deep-pocket players such as Eli Lilly with a market cap of $567 billion, Pfizer with a market cap of $166 billion, Amgen with a market cap of $143 billion, and others such as Structure Therapeutics, Viking Therapeutics and Herbalife. In July 2021, following the approval for the weight loss drug, its market cap hovered at $190 billion. The race includes deep-pocket players such as Eli Lilly with a market cap of $567 billion, Pfizer with a market cap of $166 billion, Amgen with a market cap of $143 billion, and others such as Structure Therapeutics, Viking Therapeutics and Herbalife.

Source: Indian Express November 11, 2023 19:09 UTC